Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia

[1]  N. Saquib,et al.  Time-varying effects of prognostic factors associated with disease-free survival in breast cancer. , 2009, American journal of epidemiology.

[2]  Sean Davis,et al.  Molecular Grading of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[3]  Mitch Dowsett,et al.  Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[4]  R. Vierkant,et al.  Assessment of the accuracy of the Gail model in women with atypical hyperplasia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Luini,et al.  Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity , 2008, British Journal of Cancer.

[6]  R. Vierkant,et al.  Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. , 2008, Journal of the National Cancer Institute.

[7]  R. Vierkant,et al.  Stratification of breast cancer risk in women with atypia: a Mayo cohort study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Kai Zhang,et al.  Utility of SKP2 and MIB-1 in grading follicular lymphoma using quantitative imaging analysis. , 2007, Human pathology.

[9]  Mikael Lundin,et al.  Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series. , 2006, European journal of cancer.

[10]  Romayne A. Thompson,et al.  Age-related lobular involution and risk of breast cancer. , 2006, Journal of the National Cancer Institute.

[11]  M. Ellis,et al.  Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Cazzaniga,et al.  Atypia and Ki-67 Expression from Ductal Lavage in Women at Different Risk for Breast Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[13]  P. Thomas,et al.  Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in‐situ hybridization in the evaluation of HER‐2/neu expression in primary breast carcinoma , 2006, Histopathology.

[14]  P. Tartter,et al.  Immunohistochemical staining for cyclin D1 and Ki-67 aids in the stratification of atypical ductal hyperplasia diagnosed on breast core biopsy. , 2005, American journal of clinical pathology.

[15]  C Sotiriou,et al.  Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Mitch Dowsett,et al.  Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  V Shane Pankratz,et al.  Benign breast disease and the risk of breast cancer. , 2005, The New England journal of medicine.

[18]  R. Mansel,et al.  Benign breast disorders. , 2005, The New England journal of medicine.

[19]  C. Zalles,et al.  Ki-67 Expression in Benign Breast Ductal Cells Obtained by Random Periareolar Fine Needle Aspiration , 2005, Cancer Epidemiology Biomarkers & Prevention.

[20]  L. Ford,et al.  Prevention of hormone-related cancers: breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Adami,et al.  Prognostic implication of estrogen receptor content in breast cancer , 2005, Breast Cancer Research and Treatment.

[22]  K. Bloom,et al.  Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. , 2004, American journal of clinical pathology.

[23]  K. Hess,et al.  Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse , 2003, Breast Cancer Research and Treatment.

[24]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[25]  J. Sloane,et al.  Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. , 2002, The American journal of pathology.

[26]  A. Thor,et al.  Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Sloane,et al.  Immunodetectable cyclin D 1 is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions , 2001, British Journal of Cancer.

[28]  S. Fuqua,et al.  Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.

[29]  R. Chlebowski.  Reducing the risk of breast cancer. , 2000, The New England journal of medicine.

[30]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[31]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[32]  S. Haga,et al.  Prognostic significance of MIB1-determined proliferative activities in intraductal components and invasive foci associated with invasive ductal breast carcinoma , 1999, British Journal of Cancer.

[33]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[34]  M. Gnant,et al.  p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. , 1997, European journal of cancer.

[35]  G. Colditz,et al.  A prospective study of benign breast disease and the risk of breast cancer , 1992, JAMA.

[36]  W. Dupont,et al.  Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .

[37]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[38]  P. Mullins,et al.  Progesterone and estrogen receptors as prognostic variables in breast cancer. , 1983, Cancer research.

[39]  Johannes Gerdes,et al.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation , 1983, International journal of cancer.